FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2939294080> ?p ?o ?g. }

• W2939294080 abstract "Since the introduction of imatinib, the first oral tyrosine kinase inhibitor (TKI) targeting the Philadelphia Chromosome, the prognosis in chronic myelogenous leukaemia (CML) has dramatically improved.1 Although there have been multiple reports demonstrating a T/Natural Killer (NK) cell monoclonal lymphocytosis with the use of dasatinib and some studies showing a small increased risk of second malignancies with the use of TKIs in CML, an association between nilotinib and rare haematological malignancies has not been established.2–6 Herein, we report the first case of T-cell prolymphocytic leukaemia (T-PLL) occurring in a patient with CML in sustained deep-molecular response after nilotinib therapy.A patient in her 60s (age) was diagnosed with chronic phase CML in 2008. The karyotype at diagnosis showed the classic Philadelphia chromosome (46,XX,t(9;22)(q34;q11)). Real-time quantitative polymerase chain reaction (RT qPCR) for BCR-ABL1 detected an e14a2 transcript type. She was started on first-line nilotinib 400 mg two times a day as part of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) trial (a randomised controlled trial comparing nilotinib at two doses of 300 mg two times a day and 400 mg two times a day, with imatinib 400 mg once a day). She achieved optimal response at 3 months of treatment as per the 2013 European Leukaemia Net (ELN) guidelines and 5-log reduction (MR5; RT qPCR for …" @default.
• W2939294080 created "2019-04-25" @default.
• W2939294080 creator A5008643238 @default.
• W2939294080 creator A5009798359 @default.
• W2939294080 creator A5009840248 @default.
• W2939294080 creator A5021096423 @default.
• W2939294080 creator A5022520620 @default.
• W2939294080 creator A5025855928 @default.
• W2939294080 creator A5033114100 @default.
• W2939294080 creator A5039074335 @default.
• W2939294080 creator A5060745448 @default.
• W2939294080 creator A5074115908 @default.
• W2939294080 creator A5086020780 @default.
• W2939294080 date "2019-04-19" @default.
• W2939294080 modified "2023-09-23" @default.
• W2939294080 title "T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report" @default.
• W2939294080 cites W2005895687 @default.
• W2939294080 cites W2073035156 @default.
• W2939294080 cites W2090293697 @default.
• W2939294080 cites W2143320043 @default.
• W2939294080 cites W2160811827 @default.
• W2939294080 cites W2310036617 @default.
• W2939294080 cites W2521948287 @default.
• W2939294080 doi "https://doi.org/10.1136/jclinpath-2019-205799" @default.
• W2939294080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31004076" @default.
• W2939294080 hasPublicationYear "2019" @default.
• W2939294080 type Work @default.
• W2939294080 sameAs 2939294080 @default.
• W2939294080 citedByCount "1" @default.
• W2939294080 countsByYear W29392940802019 @default.
• W2939294080 crossrefType "journal-article" @default.
• W2939294080 hasAuthorship W2939294080A5008643238 @default.
• W2939294080 hasAuthorship W2939294080A5009798359 @default.
• W2939294080 hasAuthorship W2939294080A5009840248 @default.
• W2939294080 hasAuthorship W2939294080A5021096423 @default.
• W2939294080 hasAuthorship W2939294080A5022520620 @default.
• W2939294080 hasAuthorship W2939294080A5025855928 @default.
• W2939294080 hasAuthorship W2939294080A5033114100 @default.
• W2939294080 hasAuthorship W2939294080A5039074335 @default.
• W2939294080 hasAuthorship W2939294080A5060745448 @default.
• W2939294080 hasAuthorship W2939294080A5074115908 @default.
• W2939294080 hasAuthorship W2939294080A5086020780 @default.
• W2939294080 hasConcept C104317684 @default.
• W2939294080 hasConcept C121608353 @default.
• W2939294080 hasConcept C126322002 @default.
• W2939294080 hasConcept C138626823 @default.
• W2939294080 hasConcept C143998085 @default.
• W2939294080 hasConcept C2776960273 @default.
• W2939294080 hasConcept C2777413986 @default.
• W2939294080 hasConcept C2777583451 @default.
• W2939294080 hasConcept C2778461978 @default.
• W2939294080 hasConcept C2778729363 @default.
• W2939294080 hasConcept C2778820342 @default.
• W2939294080 hasConcept C2778904597 @default.
• W2939294080 hasConcept C2779536868 @default.
• W2939294080 hasConcept C55493867 @default.
• W2939294080 hasConcept C71924100 @default.
• W2939294080 hasConcept C86803240 @default.
• W2939294080 hasConcept C90924648 @default.
• W2939294080 hasConceptScore W2939294080C104317684 @default.
• W2939294080 hasConceptScore W2939294080C121608353 @default.
• W2939294080 hasConceptScore W2939294080C126322002 @default.
• W2939294080 hasConceptScore W2939294080C138626823 @default.
• W2939294080 hasConceptScore W2939294080C143998085 @default.
• W2939294080 hasConceptScore W2939294080C2776960273 @default.
• W2939294080 hasConceptScore W2939294080C2777413986 @default.
• W2939294080 hasConceptScore W2939294080C2777583451 @default.
• W2939294080 hasConceptScore W2939294080C2778461978 @default.
• W2939294080 hasConceptScore W2939294080C2778729363 @default.
• W2939294080 hasConceptScore W2939294080C2778820342 @default.
• W2939294080 hasConceptScore W2939294080C2778904597 @default.
• W2939294080 hasConceptScore W2939294080C2779536868 @default.
• W2939294080 hasConceptScore W2939294080C55493867 @default.
• W2939294080 hasConceptScore W2939294080C71924100 @default.
• W2939294080 hasConceptScore W2939294080C86803240 @default.
• W2939294080 hasConceptScore W2939294080C90924648 @default.
• W2939294080 hasFunder F4320336039 @default.
• W2939294080 hasLocation W29392940801 @default.
• W2939294080 hasLocation W29392940802 @default.
• W2939294080 hasOpenAccess W2939294080 @default.
• W2939294080 hasPrimaryLocation W29392940801 @default.
• W2939294080 hasRelatedWork W1827517323 @default.
• W2939294080 hasRelatedWork W1965749310 @default.
• W2939294080 hasRelatedWork W2008225112 @default.
• W2939294080 hasRelatedWork W2018942006 @default.
• W2939294080 hasRelatedWork W2182019407 @default.
• W2939294080 hasRelatedWork W2250942189 @default.
• W2939294080 hasRelatedWork W2360725119 @default.
• W2939294080 hasRelatedWork W2513574873 @default.
• W2939294080 hasRelatedWork W2557832544 @default.
• W2939294080 hasRelatedWork W2579023027 @default.
• W2939294080 hasRelatedWork W2801418858 @default.
• W2939294080 hasRelatedWork W2889475285 @default.
• W2939294080 hasRelatedWork W2909642323 @default.
• W2939294080 hasRelatedWork W2973170708 @default.
• W2939294080 hasRelatedWork W2980100481 @default.
• W2939294080 hasRelatedWork W2981767993 @default.
• W2939294080 hasRelatedWork W3022589515 @default.
• W2939294080 hasRelatedWork W3173034120 @default.
• W2939294080 hasRelatedWork W2007550939 @default.

• next